http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : 민용기 (검색결과 268 건)
- 무료
- 기관 내 무료
- 유료
-
-
당뇨병성 케톤산증 및 고중성지방혈증으로 인한 급성 췌장염으로 발현한 말단비대증 환자 1예
민용기,이춘영,이문규,이선영,홍성노,김형훈,강보현,강한욱,이병완,박유정,이명식,김광원,김종현 대한내분비학회 2002 Endocrinology and metabolism Vol.17 No.1
Secondary diabetes mellitus caused by increased growth hormone secretion (GH) has well been known. There is a close association between glucose intolerance and GH secretion, and increased GH level itself probably worsens the blood glucose control and lipid profile by increasing glycogenolysis and / or gluconeogenesis and by suppressing lipase activity. We report a case of acromegaly with diabetic ketoacidosis as and hypertriglyceridemia-induced acute pancreatitis. A 38 year old male, previously diagnosed to have acromegaly and diabetes, presented with nausea, vomiting, diffuse abdominal pain and altered mentality. There was no history of drug or alcohol consumption, blood gas analysis showed severe acidosis and urinanalysis for ketone was positive. His serum blood glucose, amylase and lipase levels were 494 ㎎/dL, 331 U/L, and 1288 U/L, respectively (reference values: 70∼110 ㎎/dL, 13∼100 U/L and 13∼190 U/L, respectively). The patient was diagnosed as having diabetic ketoacidosis and acute pancreatitis. With the serum concentration of triglyceride being 1488 ㎎/dL and the absence of any obvious precipitating factors, we considered hypertriglyceridemia to be the cause of acute pancreatitis. He was treated with continuous intravenous insulin infusion, lipid lowering agent, and fluid replacement. After conservative management, general condition gradually improved and his serum amylase, lipase and triglyceride levels were all normalized. GH level was not suppressed under 2 ng/mL during oral glucose loading test, and basal GH and IGF levels were 231 ng/mL and 29.5 ng/mL, respectively. Sella MRI showed a 3.7 ㎝ sized pituitary mass. On the 55th day of admission, transsphenoidal surgery was performed. In immunohistochemical staining, the pathologic tumor specimen was proved to be GH positive pituitary adenoma. This is the first case reported in the English literature of an acromegaly presenting with diabetic ketoacidosis and acute pancreatitis
-
민용기,박영태 계명대학교 자연과학연구소 2022 Quantitative Bio-Science Vol.41 No.1
Co-oligomerizations of 2,6-dilithio-4,4-diisopropyl- or -diphenyl-dithieno[3,2-b:2′,3′-d]siloles, which were prepared in situ via n-butyllithium treatment of 2,6-dibromo-4,4-diisopropyl- or -diphenyl-dithieno[3,2-b:2′,3′-d]siloles (V or VI), with dichlorodiisopropylsilane or dichlorodiphenylsilane yielded the novel oligomers oligo[(4,4-disubstituted-2,6- dithieno[3,2-b:2′,3′-d]silolene)-alt-(disubstituted silylene)]s VII-X as blue-greenish viscous liquids. These oligomers were characterized using several spectroscopic methods, such as 1H and 13C nuclear magnetic resonance spectroscopy and Fourier transform infrared spectroscopy, photophysical properties, and thermal stabilities, along with density functional theory (DFT) calculations. The absorption spectra of VII, VIII, and X, in particular, revealed partial delocalization over the oligomer backbones in comparison with those of the monomers V and VI, which was consistent with the highest occupied molecular orbital-lowest unoccupied molecular orbital energy trends calculated using DFT. VII-X were generally stable up to 150°C, with the less than 4% loss of the original mass.
-
-
-
-
Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis
민용기 대한내분비학회 2015 Endocrinology and metabolism Vol.30 No.1
Denosumab, a fully human recombinant monoclonal antibody to the receptor activator of nuclear factor-κB ligand (RANKL), blocks binding of RANKL to the RANK receptor, found on the surface of osteoclasts and osteoclast precursors, resulting in decreased bone resorption. Subcutaneous denosumab administration once every 6 months increases bone mineral density at the lumbar spine, total hip, and/or femoral neck, and reduces markers of bone turnover significantly in postmenopausal women with osteoporosis. Relative to placebo, denosumab treatment reduces the risk of vertebral, nonvertebral, and hip fractures significantly. The benefits of denosumab treatment are generally obvious after the first dose and were continued for up to 8 years of treatment in an extension study. The tolerability profile of denosumab during this extension phase was consistent with that observed during the initial 3-year FREEDOM trial. Postmarketing safety surveillance has not shown any unexpected findings. Ongoing safety surveillance will more fully define the long-term safety of denosumab. The benefits of denosumab would seem to be greater than its risks. Denosumab is an important choice in the treatment of postmenopausal women with osteoporosis at increased risk of fractures, including older patients who have difficulty with oral bisphosphonate intake and patients who are intolerant of, or unresponsive to, other therapies.
-
-
-
KCI
DBpia연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
